Source comparison
MOTS-c Dosing Protocols: Research Application Comparison
Insulin Sensitivity Improvement 5mg 3×/week 8–12 weeks 30–60 min before largest meal Lower doses sufficient. AMPK-mediated GLUT4 translocation is dose-responsive up to ~7mg, then plateaus Fat Oxidation & Mitochondrial Biogenesis 10–15mg 12–16 weeks 45–60 min b
This comparison does not assign a generated winner or score.
- Insulin Sensitivity Improvement
- 5mg
- 3×/week
- 8–12 weeks
- 30–60 min before largest meal
- Lower doses sufficient. AMPK-mediated GLUT4 translocation is dose-responsive up to ~7mg, then plateaus
- Fat Oxidation & Mitochondrial Biogenesis
- 10–15mg
- 12–16 weeks
- 45–60 min before exercise or fasted morning injection
- Higher doses required to sustain PGC-1α upregulation. Combine with caloric deficit for maximal effect
- Exercise Performance Enhancement
- 10mg
- 6–10 weeks
- 60 min pre-workout
- MOTS-c amplifies exercise-induced AMPK activation. Synergistic with resistance or endurance training
- Age-Related Metabolic Decline
- 5–10mg
- 2–3×/week
- Ongoing
- 30 min before breakfast
- Chronic low-dose administration shown in rodent models to preserve mitochondrial function without tachyphylaxis
- Professional Assessment
- Start at 5mg to assess tolerance. Titrate to 10–15mg based on metabolic markers (fasting glucose, insulin sensitivity, body composition). MOTS-c does not cause receptor downregulation like chronic GLP-1 agonist use. Sustained efficacy observed across 16+ week rodent studies.
- Human trials are limited; dosing extrapolated from rodent mg/kg equivalents and anecdotal research use.